Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

6. ledna 2022 aktualizováno: Novo Nordisk A/S

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

1264

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Argentina
      • Caba, Argentina, C1060ABA
        • Novo Nordisk Investigational Site
      • Caba, Argentina, C1440AAD
        • Novo Nordisk Investigational Site
      • Cordoba, Argentina, 5000
        • Novo Nordisk Investigational Site
      • Córdoba, Argentina, 5008
        • Novo Nordisk Investigational Site
  • Bulharsko
      • Kozloduy, Bulharsko, 3320
        • Novo Nordisk Investigational Site
      • Razgrad, Bulharsko, 7200
        • Novo Nordisk Investigational Site
      • Sofia, Bulharsko, 1233
        • Novo Nordisk Investigational Site
      • Sofia, Bulharsko, 1618
        • Novo Nordisk Investigational Site
  • Chorvatsko
      • Karlovac, Chorvatsko, 47000
        • Novo Nordisk Investigational Site
      • Osijek, Chorvatsko, 31 000
        • Novo Nordisk Investigational Site
      • Varazdin, Chorvatsko, 42 000
        • Novo Nordisk Investigational Site
      • Zagreb, Chorvatsko, 10 000
        • Novo Nordisk Investigational Site
  • Itálie
      • Catanzaro, Itálie, 88100
        • Novo Nordisk Investigational Site
      • Chieti, Itálie, 66100
        • Novo Nordisk Investigational Site
      • Cittadella (PD), Itálie, 35013
        • Novo Nordisk Investigational Site
      • Milano (MI), Itálie, 20132
        • Novo Nordisk Investigational Site
      • Olbia, Itálie, 07026
        • Novo Nordisk Investigational Site
      • Palermo, Itálie, 90129
        • Novo Nordisk Investigational Site
  • Kanada
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2E1
        • Novo Nordisk Investigational Site
    • British Columbia
      • Victoria, British Columbia, Kanada, V8V 4A1
        • Novo Nordisk Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
        • Novo Nordisk Investigational Site
    • Ontario
      • Barrie, Ontario, Kanada, L4N 7L3
        • Novo Nordisk Investigational Site
      • Concord, Ontario, Kanada, L4K 4M2
        • Novo Nordisk Investigational Site
      • Etobicoke, Ontario, Kanada, M9R 4E1
        • Novo Nordisk Investigational Site
      • Hamilton, Ontario, Kanada, L8M 1K7
        • Novo Nordisk Investigational Site
      • Newmarket, Ontario, Kanada, L3Y 5G8
        • Novo Nordisk Investigational Site
      • Thunder Bay, Ontario, Kanada, P7A 4V7
        • Novo Nordisk Investigational Site
      • Toronto, Ontario, Kanada, M4G 3E8
        • Novo Nordisk Investigational Site
    • Quebec
      • Montreal, Quebec, Kanada, H4T 1Z9
        • Novo Nordisk Investigational Site
  • Korejská republika
      • Bucheon, Korejská republika, 14647
        • Novo Nordisk Investigational Site
      • Daegu, Korejská republika, 42472
        • Novo Nordisk Investigational Site
      • Seongnam-si, Korejská republika, 463-707
        • Novo Nordisk Investigational Site
      • Seoul, Korejská republika, 02447
        • Novo Nordisk Investigational Site
      • Seoul, Korejská republika, 03080
        • Novo Nordisk Investigational Site
      • Seoul, Korejská republika, 04516
        • Novo Nordisk Investigational Site
      • Seoul, Korejská republika, 06351
        • Novo Nordisk Investigational Site
      • Seoul, Korejská republika, 08308
        • Novo Nordisk Investigational Site
      • Seoul, Korejská republika, 137-701
        • Novo Nordisk Investigational Site
      • Wonju, Korejská republika, 26426
        • Novo Nordisk Investigational Site
  • Německo
      • Dresden, Německo, 01219
        • Novo Nordisk Investigational Site
      • Essen, Německo, 45136
        • Novo Nordisk Investigational Site
      • Falkensee, Německo, 14612
        • Novo Nordisk Investigational Site
      • Lingen, Německo, 49808
        • Novo Nordisk Investigational Site
      • Münster, Německo, 48145
        • Novo Nordisk Investigational Site
      • Saint Ingbert-Oberwürzbach, Německo, 66386
        • Novo Nordisk Investigational Site
      • Schweinfurt, Německo, 97421
        • Novo Nordisk Investigational Site
  • Polsko
      • Bialystok, Polsko, 15-435
        • Novo Nordisk Investigational Site
      • Skorzewo, Polsko, 60-185
        • Novo Nordisk Investigational Site
      • Warsaw, Polsko, 00-465
        • Novo Nordisk Investigational Site
      • Warsaw, Polsko, 02-793
        • Novo Nordisk Investigational Site
      • Warszawa, Polsko, 02-507
        • Novo Nordisk Investigational Site
      • Wroclaw, Polsko, 50-381
        • Novo Nordisk Investigational Site
  • Portoriko
      • Ponce, Portoriko, 00716
        • Novo Nordisk Investigational Site
  • Rumunsko
      • Brasov, Rumunsko, 500101
        • Novo Nordisk Investigational Site
      • Brasov, Rumunsko, 500283
        • Novo Nordisk Investigational Site
      • Bucharest, Rumunsko, 13682
        • Novo Nordisk Investigational Site
    • Maramures
      • Baia Mare, Maramures, Rumunsko, 430222
        • Novo Nordisk Investigational Site
    • Mures
      • Tirgu Mures, Mures, Rumunsko, 540142
        • Novo Nordisk Investigational Site
    • Timis
      • Timisoara, Timis, Rumunsko, 300125
        • Novo Nordisk Investigational Site
  • Ruská Federace
      • Arkhangelsk, Ruská Federace, 163045
        • Novo Nordisk Investigational Site
      • Kazan, Ruská Federace, 420073
        • Novo Nordisk Investigational Site
      • Moscow, Ruská Federace, 123448
        • Novo Nordisk Investigational Site
      • Penza, Ruská Federace, 440026
        • Novo Nordisk Investigational Site
      • Saint Petersburg, Ruská Federace, 194291
        • Novo Nordisk Investigational Site
      • Saint-Petersburg, Ruská Federace, 194356
        • Novo Nordisk Investigational Site
      • Tumen, Ruská Federace, 625023
        • Novo Nordisk Investigational Site
      • Voronezh, Ruská Federace, 394018
        • Novo Nordisk Investigational Site
  • Slovensko
      • Kosice, Slovensko, 040 01
        • Novo Nordisk Investigational Site
      • Kysucke Nove Mesto, Slovensko, 024 01
        • Novo Nordisk Investigational Site
      • Lubochna, Slovensko, 03491
        • Novo Nordisk Investigational Site
      • Lucenec, Slovensko, 984 01
        • Novo Nordisk Investigational Site
      • Zilina, Slovensko, 01001
        • Novo Nordisk Investigational Site
  • Spojené státy
    • California
      • Concord, California, Spojené státy, 94520
        • Novo Nordisk Investigational Site
      • Fresno, California, Spojené státy, 93720
        • Novo Nordisk Investigational Site
      • Fullerton, California, Spojené státy, 92835
        • Novo Nordisk Investigational Site
      • Lancaster, California, Spojené státy, 93534
        • Novo Nordisk Investigational Site
      • Norco, California, Spojené státy, 92860
        • Novo Nordisk Investigational Site
      • Sacramento, California, Spojené státy, 95821
        • Novo Nordisk Investigational Site
      • Ventura, California, Spojené státy, 93003
        • Novo Nordisk Investigational Site
      • Walnut Creek, California, Spojené státy, 94598
        • Novo Nordisk Investigational Site
    • Colorado
      • Denver, Colorado, Spojené státy, 80246
        • Novo Nordisk Investigational Site
      • Golden, Colorado, Spojené státy, 80401
        • Novo Nordisk Investigational Site
    • Connecticut
      • Waterbury, Connecticut, Spojené státy, 06708
        • Novo Nordisk Investigational Site
    • Florida
      • Boynton Beach, Florida, Spojené státy, 33472
        • Novo Nordisk Investigational Site
      • Bradenton, Florida, Spojené státy, 34201
        • Novo Nordisk Investigational Site
      • Fort Lauderdale, Florida, Spojené státy, 33312
        • Novo Nordisk Investigational Site
      • Miami, Florida, Spojené státy, 33174
        • Novo Nordisk Investigational Site
      • Tampa, Florida, Spojené státy, 33634
        • Novo Nordisk Investigational Site
    • Georgia
      • Alpharetta, Georgia, Spojené státy, 30022
        • Novo Nordisk Investigational Site
      • Lawrenceville, Georgia, Spojené státy, 30046
        • Novo Nordisk Investigational Site
      • Roswell, Georgia, Spojené státy, 30076
        • Novo Nordisk Investigational Site
    • Hawaii
      • Honolulu, Hawaii, Spojené státy, 96814
        • Novo Nordisk Investigational Site
    • Illinois
      • Chicago, Illinois, Spojené státy, 60611
        • Novo Nordisk Investigational Site
      • Peoria, Illinois, Spojené státy, 61603
        • Novo Nordisk Investigational Site
      • Springfield, Illinois, Spojené státy, 62711
        • Novo Nordisk Investigational Site
    • Indiana
      • Valparaiso, Indiana, Spojené státy, 46383
        • Novo Nordisk Investigational Site
    • Iowa
      • West Des Moines, Iowa, Spojené státy, 50266
        • Novo Nordisk Investigational Site
    • Kansas
      • Topeka, Kansas, Spojené státy, 66606
        • Novo Nordisk Investigational Site
    • Kentucky
      • Lexington, Kentucky, Spojené státy, 40503
        • Novo Nordisk Investigational Site
      • Lexington, Kentucky, Spojené státy, 40502
        • Novo Nordisk Investigational Site
    • Maryland
      • Rockville, Maryland, Spojené státy, 20852
        • Novo Nordisk Investigational Site
    • Massachusetts
      • Waltham, Massachusetts, Spojené státy, 02453
        • Novo Nordisk Investigational Site
      • Worcester, Massachusetts, Spojené státy, 01655
        • Novo Nordisk Investigational Site
    • Nevada
      • Henderson, Nevada, Spojené státy, 89052-2649
        • Novo Nordisk Investigational Site
      • Las Vegas, Nevada, Spojené státy, 89148
        • Novo Nordisk Investigational Site
    • New Hampshire
      • Nashua, New Hampshire, Spojené státy, 03063
        • Novo Nordisk Investigational Site
    • New York
      • Northport, New York, Spojené státy, 11768
        • Novo Nordisk Investigational Site
      • West Seneca, New York, Spojené státy, 14224
        • Novo Nordisk Investigational Site
    • North Carolina
      • Asheville, North Carolina, Spojené státy, 28803
        • Novo Nordisk Investigational Site
      • Chapel Hill, North Carolina, Spojené státy, 27514
        • Novo Nordisk Investigational Site
    • Ohio
      • Mentor, Ohio, Spojené státy, 44060
        • Novo Nordisk Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Spojené státy, 73104-5020
        • Novo Nordisk Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19140
        • Novo Nordisk Investigational Site
    • South Carolina
      • Greenville, South Carolina, Spojené státy, 29605-4254
        • Novo Nordisk Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, Spojené státy, 37404
        • Novo Nordisk Investigational Site
      • Chattanooga, Tennessee, Spojené státy, 37411
        • Novo Nordisk Investigational Site
      • Nashville, Tennessee, Spojené státy, 37212
        • Novo Nordisk Investigational Site
    • Texas
      • Amarillo, Texas, Spojené státy, 79106
        • Novo Nordisk Investigational Site
      • Austin, Texas, Spojené státy, 78731
        • Novo Nordisk Investigational Site
      • Austin, Texas, Spojené státy, 78749
        • Novo Nordisk Investigational Site
      • Beaumont, Texas, Spojené státy, 77701
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Spojené státy, 75230
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Spojené státy, 75226
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Spojené státy, 75231
        • Novo Nordisk Investigational Site
      • Longview, Texas, Spojené státy, 75605
        • Novo Nordisk Investigational Site
      • Pearland, Texas, Spojené státy, 77584
        • Novo Nordisk Investigational Site
      • Round Rock, Texas, Spojené státy, 78681
        • Novo Nordisk Investigational Site
    • Utah
      • Ogden, Utah, Spojené státy, 84405
        • Novo Nordisk Investigational Site
    • Vermont
      • Bennington, Vermont, Spojené státy, 05201
        • Novo Nordisk Investigational Site
      • South Burlington, Vermont, Spojené státy, 05403
        • Novo Nordisk Investigational Site
    • Virginia
      • Chesapeake, Virginia, Spojené státy, 23321
        • Novo Nordisk Investigational Site
      • Winchester, Virginia, Spojené státy, 22601-3834
        • Novo Nordisk Investigational Site
    • Washington
      • Olympia, Washington, Spojené státy, 98502
        • Novo Nordisk Investigational Site
      • Seattle, Washington, Spojené státy, 98105
        • Novo Nordisk Investigational Site
      • Spokane, Washington, Spojené státy, 99201
        • Novo Nordisk Investigational Site
    • Wisconsin
      • Green Bay, Wisconsin, Spojené státy, 54303
        • Novo Nordisk Investigational Site
  • Srbsko
      • Belgrade, Srbsko, 11000
        • Novo Nordisk Investigational Site
      • Kragujevac, Srbsko, 34000
        • Novo Nordisk Investigational Site
      • Nis, Srbsko, 18000
        • Novo Nordisk Investigational Site
      • Novi Sad, Srbsko, 21000
        • Novo Nordisk Investigational Site
      • Zajecar, Srbsko, 19000
        • Novo Nordisk Investigational Site
  • Ukrajina
      • Dnipro, Ukrajina, 49038
        • Novo Nordisk Investigational Site
      • Kharkiv, Ukrajina, 61000
        • Novo Nordisk Investigational Site
      • Kyiv, Ukrajina, 03049
        • Novo Nordisk Investigational Site
      • Lviv, Ukrajina, 79010
        • Novo Nordisk Investigational Site
      • Ternopil, Ukrajina, 46002
        • Novo Nordisk Investigational Site
      • Vinnytsia, Ukrajina, 21010
        • Novo Nordisk Investigational Site
  • Česko
      • Hradec Kralove, Česko, 500 05
        • Novo Nordisk Investigational Site
      • Plzen, Česko, 30100
        • Novo Nordisk Investigational Site
      • Plzen, Česko, 32600
        • Novo Nordisk Investigational Site
      • Trutnov, Česko, 541 01
        • Novo Nordisk Investigational Site
  • Řecko
      • Athens, Řecko, GR-11527
        • Novo Nordisk Investigational Site
      • Athens, Řecko, 115 25
        • Novo Nordisk Investigational Site
      • Ioannina, Řecko, 45500
        • Novo Nordisk Investigational Site
      • Larissa, Řecko, GR-41110
        • Novo Nordisk Investigational Site
      • Thessaloniki, Řecko, GR-54636
        • Novo Nordisk Investigational Site
      • Thessaloniki, Řecko, GR-57001
        • Novo Nordisk Investigational Site
      • Thessaloniki, Řecko, GR-54642
        • Novo Nordisk Investigational Site
      • Thessaloniki, Řecko, GR-54643
        • Novo Nordisk Investigational Site
  • Španělsko
      • Alcobendas, Španělsko, 28100
        • Novo Nordisk Investigational Site
      • Almería, Španělsko, 04001
        • Novo Nordisk Investigational Site
      • Girona, Španělsko, 17007
        • Novo Nordisk Investigational Site
      • La Coruña, Španělsko, 15006
        • Novo Nordisk Investigational Site
      • Pozuelo de Alarcon, Španělsko, 28223
        • Novo Nordisk Investigational Site
      • Sabadell, Španělsko, 08208
        • Novo Nordisk Investigational Site
      • Sevilla, Španělsko, 41010
        • Novo Nordisk Investigational Site
      • Sevilla, Španělsko, 41003
        • Novo Nordisk Investigational Site

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble insulin combination is not considered a basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). - Subjects presently classified as being in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (Visit 1). - Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Faster aspart + insulin degludec with or without metformin
Lék: Faster-acting insulin aspart
Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Lék: Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Lék: Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Aktivní komparátor: NovoRapid/NovoLog + insulin degludec with or without metformin
Lék: Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Lék: Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Lék: Insulin aspart
Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Glycosylated Haemoglobin (HbA1c)
Časové okno: Week 0, week 16
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change From Baseline in 1-hour PPG Increment
Časové okno: Week 0, week 16
Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in 1,5-anhydroglucitol
Časové okno: Week 0, week 16
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in Fasting Plasma Glucose (FPG)
Časové okno: Week 0, week 16
Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No)
Časové okno: 16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No)
Časové okno: 16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test])
Časové okno: Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG [meal test]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
Week 0, week 16
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)
Časové okno: Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value.
Week 0, week 16
Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile
Časové okno: Week 0, week 16
Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)
Časové okno: Week 0, week 16
Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)
Časové okno: Week 0, week 16
Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile
Časové okno: Week 0, week 16
Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements
Časové okno: Week 0, week 16
Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No)
Časové okno: 16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No)
Časové okno: 16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Total Bolus Insulin Dose: in Units/Day
Časové okno: 16 weeks from randomisation
Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Bolus Insulin Dose: in Units/kg/Day
Časové okno: 16 weeks from randomisation
Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/Day
Časové okno: 16 weeks from randomisation
Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/kg/Day
Časové okno: 16 weeks from randomisation
Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units
Časové okno: 16 weeks from randomisation
Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units/kg
Časové okno: 16 weeks from randomisation
Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline
Časové okno: Week 0, week 16
Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Number of Treatment Emergent Adverse Events
Časové okno: Weeks 0-16
Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Injection Site Reactions
Časové okno: Weeks 0-16
Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall
Časové okno: Weeks 0-16

ADA classification of hypos:

  1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level.
  2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms.
  3. Asymptomatic: PG ≤3.9 mmol/L without symptoms.
  4. Probable symptomatic: No measurement with symptoms.
  5. Pseudo: PG >3.9 mmol/L with symptoms.
  6. Unclassifiable.

NN classification of hypos:

  1. BG confirmed: PG <3.1 mmol/L with/without symptoms.
  2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with symptoms.
  3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with/without symptoms.
  4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)
Časové okno: Weeks 0-16
Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
Časové okno: Weeks 0-16
Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal
Časové okno: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal
Časové okno: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal
Časové okno: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal
Časové okno: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Change From Baseline in Physical Examination
Časové okno: Week 0, week 16
Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central & Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin
Week 0, week 16
Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure
Časové okno: Week 0, week 16
Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Vital Signs: Pulse
Časové okno: Week 0, week 16
Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Electrocardiogram (ECG)
Časové okno: Week 0, week 16
Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Fundoscopy/Fundus Photography
Časové okno: Week 0, week 16
Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haematocrit
Časové okno: Week 0, week 16
Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haemoglobin
Časové okno: Week 0, week 16
Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Leukocytes
Časové okno: Week 0, week 16
Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Thrombocytes
Časové okno: Week 0, week 16
Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Erythrocytes
Časové okno: Week 0, week 16
Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT)
Časové okno: Week 0, week 16
Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alkaline Phosphatase
Časové okno: Week 0, week 16
Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST)
Časové okno: Week 0, week 16
Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Albumin
Časové okno: Week 0, week 16
Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Creatinine
Časové okno: Week 0, week 16
Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Potassium
Časové okno: Week 0, week 16
Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Sodium
Časové okno: Week 0, week 16
Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Bilirubin
Časové okno: Week 0, week 16
Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Protein
Časové okno: Week 0, week 16
Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Weight
Časové okno: Week 0, week 16
Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Mass Index (BMI)
Časové okno: Week 0, week 16
Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Novo Nordisk A/S

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

19. září 2017

Primární dokončení (Aktuální)

7. ledna 2019

Dokončení studie (Aktuální)

29. ledna 2019

Termíny zápisu do studia

První předloženo

29. srpna 2017

První předloženo, které splnilo kritéria kontroly kvality

29. srpna 2017

První zveřejněno (Aktuální)

31. srpna 2017

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

11. ledna 2022

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

6. ledna 2022

Naposledy ověřeno

1. ledna 2022

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • NN1218-4113
  • U1111-1180-0636 (Jiný identifikátor: World Health Organization (WHO))
  • 2016-000878-38 (Identifikátor registru: European Medicines Agency (EudraCT))

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

Ano

Popis plánu IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Diabetes mellitus, typ 2

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Liberia

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit